LabCompass

Naga Chalasani

Medicine · Indiana University

OpenAlex ORCID
Liver Disease Diagnosis and TreatmentLiver Disease and TransplantationDrug-Induced Hepatotoxicity and ProtectionLiver Diseases and ImmunityAlcohol Consumption and Health Effects

Publications

832

Citations

58,528

Est. group size

—

Recurring co-author estimate

Active years

34

Publishing since 1993

Research summary
AI-generated

Naga Chalasani studies liver diseases, with a focus on fatty liver conditions linked to metabolic and alcohol-related factors (now termed MASH/MASLD) and on drug-induced liver injury, where medications cause harm to the liver. The work spans clinical trials of new therapies, genetic risk factors for liver injury, and emerging tools such as artificial intelligence and machine learning applied to liver tissue analysis.

Metabolic/fatty liver disease (MASH/MASLD)Drug-induced liver injuryGenetic risk factors for liver diseaseAI and digital pathology in hepatologyClinical trials of liver disease therapies

Publication activity was very high in the late 2010s (peaking around 2020) and has run at a lower but steady pace of roughly 30-40 papers per year since 2021.

Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026

Publication cadence
Publications per year over the last 10 years — averaging 28.8/year recently
2017: 52 publications172018: 68 publications182019: 63 publications192020: 82 publications82202021: 30 publications212022: 31 publications222023: 39 publications232024: 42 publications242025: 27 publications252026: 5 publications26
Recent publications
Publishes in
  • Gastroenterology×61
  • Journal of Hepatology×38
  • Hepatology×32
  • The American Journal of Gastroenterology×32
  • Clinical Gastroenterology and Hepatology×28

This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.

Last updated Jul 11, 2026.

Claim or correct this profile